This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Chronic Obstructive Pulmonary Disease (COPD)
and you are
over 40
years old
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The purpose of this study is to compare the efficacy and safety/tolerability of indacaterol and glycopyrronium (QVA149) (fixed-dose combination) with fluticasone/salmeterol over a 26-week period in patients with moderate to severe COPD.

Provided treatments

  • Drug: indacaterol and glycopyrronium (QVA149)
  • Drug: Placebo to fluticasone/salmeterol
  • Drug: fluticasone/salmeterol
  • Drug: Placebo to indacaterol and glycopyrronium (QVA149)

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01315249. The sponsor of the trial is Novartis Pharmaceuticals and it is looking for 523 volunteers for the current phase.
Official trial title:
A 26-week Treatment, Multi-center, Randomized, Doubleblind, Double Dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease